Vaccine Science & Options
Vaccines help reduce the incidence of many diseases throughout the world.
The production of vaccines involves growing a virus in living cells. Historically they have been manufactured by using animal cell lines that contain the Deoxyribonucleic Acid (DNA) of that animal. Within the final product some residual living DNA remains as a contaminant in the vaccine as it cannot all be filtered out. In 1979, some vaccine manufacturers switched from using animal cell lines to using human fetal cell lines. Vaccines manufactured on human cells are contaminated with residual human fetal DNA and in some cases a retrovirus. This includes vaccines on both the CDC’s pediatric and adult recommended schedules. Please see our Vaccine Card to learn which brands are manufactured utilizing fetal cells.
It is a well understood scientific fact that loose, living human DNA in a human can insert into the genome of that human. As the DNA in the genes govern the function of cells, such DNA insertions can seriously disrupt the function of the invaded cell. If this loose DNA invades the genes governing the function of a nerve cell in the brain, such disruption can have devastating consequences. Sound Choice Pharmaceutical Institute (SCPI) researches the potential health risks of the residual human DNA found in some vaccines and other products .
Many scientists have now hypothesized some cancers and other childhood neurological disorders such as Autism Spectrum Disorder (ASD) may be caused by mutations in the child’s DNA. This conclusion is based upon finding numerous mutations in the brains and/or blood of such children which cannot be found in their parents. Some mutations occur at or soon after conception and are called de novo. Others are acquired mutations that occur after birth due to environmental factors or exposures and are called somatic mutations. One such event could be exposure to residual human DNA from childhood vaccines. SCPI researches have extensively reviewed the potential health risks posed by this residual human DNA. Based upon those findings, SCPI does ongoing research and seeks to raise awareness of the potential health risks of manufacturing medical products on human cell lines.